It is a fixed dose combination product containing an antihistamine (HAzelastine hydrochloride active ingredient occurs as a white or almost white, crystalline powder with a bitter taste. In these trials, the treatment differences between azelastine hydrochloride and fluticasone propionate nasal spray and the monotherapies were less than the minimum important difference of 0.5 points.The efficacy and safety of azelastine hydrochloride and fluticasone propionate nasal spray was evaluated in one randomized, multi-center, double- blind, placebo-controlled trial in 304 children 6 to 11 years of age with seasonal allergic rhinitis. Focused nasal examinations were performed and no nasal ulcerations or septal perforations were observed. How the dose, route, and duration of corticosteroid administration affect the risk of developing a disseminated infection is not known. Protect from light. If chickenpox develops, treatment with antiviral agents may be considered.Corticosteroids should be used with caution, if at all, in patients with active or quiescent tuberculous infections of the respiratory tract; untreated local or systemic fungal or bacterial infections; systemic viral or parasitic infections; or ocular herpes simplex because of the potential for worsening of these infections.When intranasal steroids are used at higher than recommended dosages or in susceptible individuals at recommended dosages, systemic corticosteroid effects such as hypercorticism and adrenal suppression may appear. A change from baseline of at least 0.5 points is considered a clinically meaningful improvement. When dry, place the spray pump unit and cap back on the bottle. In each of these trials, azelastine hydrochloride and fluticasone propionate nasal spray demonstrated a statistically significant greater decrease from baseline in the overall RQLQ than placebo, which ranged from -0.55 (95% CI -0.72, -0.39) to -0.80 (95% CI -1.05, -0.55). There may be new information. If you are a consumer or patient please visit If such changes occur, the dosage of azelastine hydrochloride and fluticasone propionate nasal spray should be discontinued slowly, consistent with accepted procedures for discontinuing oral corticosteroid therapy. Systemic bioavailability of fluticasone from azelastine hydrochloride and fluticasone propionate nasal spray following intranasal administration was 44-61% higher than monotherapy fluticasone propionate (bioavailability for monotherapy fluticasone nasal spray was less than 2%). For more information, ask your healthcare provider or pharmacist.Call your doctor for medical advice about side effects. Patients previously treated for prolonged periods with systemic corticosteroids and transferred to topical corticosteroids should be carefully monitored for acute adrenal insufficiency in response to stress. The design of this trial was similar to that of the adult trials.The primary efficacy endpoint was the mean change from baseline in combined AM+PM reflective total nasal symptom score (rTNSS) over 2 weeks. Assessment of efficacy was based on the reflective total nasal symptom score (rTNSS), in addition to the instantaneous total nasal symptom score (iTNSS) and other supportive secondary efficacy variables. Tilt your head forward slightly. No patients had reports of severe epistaxis. The population of the trials was 12 to 78 years of age (64% female, 36% male; 80% white, 16% black, 2% Asian, 1% other).Patients were randomized to one of four treatment groups: one spray per nostril twice daily of azelastine hydrochloride and fluticasone propionate nasal spray, azelastine hydrochloride nasal spray, fluticasone propionate nasal spray, and vehicle placebo. The most frequently reported adverse reactions (≥2%) with azelastine hydrochloride and fluticasone propionate nasal spray were epistaxis, headache, oropharyngeal pain, vomiting, upper abdominal pain, cough, pyrexia, otitis media, upper respiratory tract infection, diarrhea, nausea, otitis externa, and urticaria. Wash the spray pump unit and cap in warm tap water. These highlights do not include all the information needed to use AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE NASAL SPRAY safely and effectively. Get information on Azelastine nasal spray including uses, dosage details, medication side-effects and drug interaction facts from Cleveland Clinic's health library. Oral administration of azelastine hydrochloride to pregnant mice, rats, and rabbits, during the period of organogenesis, produced developmental toxicity that included structural abnormalities, decreased embryo-fetal survival, and decreased fetal body weights at doses 530 times and higher than the maximum recommended human daily intranasal dose (MRHDID) of 0.548 mg. Commonly reported side effects of azelastine nasal include: drowsiness, bitter taste, and dysgeusia. After nasal administration, azelastine is systemically absorbed with a bioavailability of about 40%. Before using azelastine (nasal) for the first time and when you haven't used it in 3 days, spray it into the air until you see a fine mist. General supportive measures should be employed if overdosage occurs. When you finish using azelastine hydrochloride and fluticasone propionate nasal spray, wipe the spray tip with a clean tissue or cloth. Azelastine hydrochloride and fluticasone propionate nasal spray, 137 mcg / 50 mcg contains 0.1% solution of azelastine hydrochloride and 0.037% suspension of micronized fluticasone propionate in an isotonic aqueous suspension containing benzalkonium chloride (0.1 mg/g), edetate disodium dihydrate, glycerin, microcrystalline cellulose and carboxymethylcellulose sodium, …